Beta-Blocker Reduces Lung Inflammation in Critical COVID-19

In a small study, intravenous administration of the beta-blocker metoprolol to critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) safely blunted lung inflammation associated with the disease. Metoprolol administration also resulted in better oxygenation and fewer days on intensive mechanical ventilation (IMV) and in the intensive care unit (ICU), compared with no treatment.

These data suggest that metoprolol repurposing for the treatment of ARDS in COVID-19 patients is a safe and inexpensive strategy with the potential to improve outcomes, the researchers say.

Links: Medscape (9/2021) (article is available open access on Medscape with free registration)